Floatz logo

Cetuximab

Lung Large Cell Carcinoma

SWOG Cancer Research Networkmonoclonal_antibodyPhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Lung Large Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Gefetinib
National Cancer Institute (NCI)
Phase 3BB
Vinorelbine
AIO-Studien-gGmbH
Phase 3BB

View all 31 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →